Agency Forms Undergoing Paperwork Reduction Act Review, 30938-30940 [2018-14172]
Download as PDF
<![CDATA[
30938
Federal Register / Vol. 83, No. 127 / Monday, July 2, 2018 / Notices
qualified candidates to apply to be
considered for appointment to the
Committee.
DATES:
Applicable: July 2, 2018.
Mr.
Ken Sandler, Office of Federal HighPerformance Buildings, GSA, 202–219–
1121.
SUPPLEMENTARY INFORMATION:
FOR FURTHER INFORMATION CONTACT:
daltland on DSKBBV9HB2PROD with NOTICES
Background
The Administrator of the GSA
established the Green Building Advisory
Committee (hereafter, ‘‘the Committee’’)
on June 20, 2011 (76 FR 118) pursuant
to Section 494 of the Energy
Independence and Security Act of 2007
(42 U.S.C. 17123, or EISA), in
accordance with the provisions of the
Federal Advisory Committee Act
(FACA), as amended (5 U.S.C. App. 2).
Under this authority, the Committee
advises GSA on how the Office of
Federal High-Performance Buildings can
most effectively accomplish its mission.
Extensive information about the
Committee, including current members,
is available on GSA’s website at https://
www.gsa.gov/gbac.
Membership requirements: The EISA
statute authorizes the Committee and
identifies the categories of members to
be included. EISA names 10 federal
agencies and offices to be represented
on the Committee, and GSA works
directly with these agencies to identify
their qualified representatives. This
notice is focused exclusively on nonfederal members. EISA provides that, in
addition to its required federal
members, the Committee shall include
‘‘other relevant agencies and entities, as
determined by the Federal Director.’’
These are to include at least one
representative of each of the following
categories:
‘‘(i) State and local governmental
green building programs;
(ii) Independent green building
associations or councils;
(iii) Building experts, including
architects, material suppliers, and
construction contractors;
(iv) Security advisors focusing on
national security needs, natural
disasters, and other dire emergency
situations;
(v) Public transportation industry
experts; and
(vi) Environmental health experts,
including those with experience in
children’s health.’’
EISA further specifies: ‘‘the total
number of non-federal members on the
Committee at any time shall not exceed
15.’’
Member responsibilities: Approved
Committee members will be appointed
VerDate Sep<11>2014
17:40 Jun 29, 2018
Jkt 244001
to terms of either 2 or 4 years with the
possibility of membership renewals as
appropriate. Membership is limited to
the specific individuals appointed and
is non-transferrable. Members are
expected to attend all meetings in
person, review all Committee materials,
and actively provide their advice and
input on topics covered by the
Committee. Committee members will
not receive compensation or travel
reimbursements from the Government
except where need has been
demonstrated and funds are available.
Request for membership nominations:
This notice provides an opportunity for
individuals to present their
qualifications and apply for an open
seat on the Committee. GSA will ask
Committee members whose terms are
expiring to re-apply if they are
interested in continuing to serve on the
Committee. GSA will review all
applications and determine which
candidates are likely to add the most
value to the Committee based on the
criteria outlined in this notice.
At a minimum, prospective members
must have:
—At least 5 years of high-performance
building experience, which may
include a combination of projectbased, research and policy
experience.
—Academic degrees, certifications and/
or training demonstrating highperformance building and related
sustainability and real estate
expertise.
—Knowledge of federal sustainability
and energy laws and programs.
—Proven ability to work effectively in a
collaborative, multi-disciplinary
environment and add value to the
work of a committee.
—Qualifications appropriate to specific
statutory requirements (listed above).
No person who is a federallyregistered lobbyist may serve on the
Committee, in accordance with the
Presidential Memorandum ‘‘Lobbyists
on Agency Boards and Commissions’’
(June 18, 2010).
Nomination process for Advisory
Committee appointment: There is no
prescribed format for the nomination.
Individuals may nominate themselves
or others. A nomination package shall
include the following information for
each nominee: (1) A letter of nomination
stating the name and organizational
affiliation(s) of the nominee,
membership capacity he/she will serve
(per statutory categories above),
nominee’s field(s) of expertise, and
description of interest and
qualifications; (2) A professional resume
or CV; and (3) Complete contact
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
information including name, return
address, email address, and daytime
telephone number of the nominee and
nominator. GSA will consider
nominations of all qualified individuals
to ensure that the Committee includes
the areas of high-performance building
subject matter expertise needed. GSA
reserves the right to choose Committee
members based on qualifications,
experience, Committee balance,
statutory requirements and all other
factors deemed critical to the success of
the Committee. Candidates may be
asked to provide detailed financial
information to permit evaluation of
potential conflicts of interest that could
impede their work on the Committee, in
accordance with the requirements of
FACA. All nominations must be
submitted in sufficient time to be
received by 5 p.m., Eastern Daylight
Time (EDT), on Thursday, July 26, 2018,
and be addressed to ken.sandler@
gsa.gov.
Dated: June 27, 2018.
Kevin Kampschroer,
Federal Director, Office of Federal HighPerformance Buildings, Office of Governmentwide Policy.
[FR Doc. 2018–14200 Filed 6–29–18; 8:45 am]
BILLING CODE 6820–14–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–18–18CV]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled Rapid Response
Suicide Investigation Data Collection to
the Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on November 9, 2017 to obtain
comments from the public and affected
agencies. CDC did not receive comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
E:\FR\FM\02JYN1.SGM
02JYN1
30939
Federal Register / Vol. 83, No. 127 / Monday, July 2, 2018 / Notices
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Direct
written comments and/or suggestions
regarding the items contained in this
notice to the Attention: CDC Desk
Officer, Office of Management and
Budget, 725 17th Street NW,
Washington, DC 20503 or by fax to (202)
395–5806. Provide written comments
within 30 days of notice publication.
Proposed Project
Rapid Response Suicide Investigation
Data Collection—New—National Center
for Injury Prevention and Control
(NCIPC), Centers for Disease Control
and Prevention (CDC)
Background and Brief Description
CDC is frequently called upon to
respond to urgent requests from one or
more external partners (e.g., local, state,
territory, and tribal health authorities;
other federal agencies; local and state
leaders; schools; or other partner
organizations) to conduct investigations
of suicide. Supporting rapid
investigations to inform the
implementation of effective suicide
prevention strategies is one of the most
important ways CDC can serve to
protect and promote the health of the
public. Prior to this request, CDC had
collected data for a suicide investigation
via the OMB-approved Emergency
Epidemic Investigations (EEI) ICR (OMB
No. 0920–1011; expiration 3/31/2020),
which supported data collections for
Epi-Aid investigations. However, this
mechanism is no longer available for
rapid suicide responses due to the
narrowing in scope of that generic. CDC
requests approval for a 3-year period for
this Generic Information Collection
Request to rapidly respond to urgent
requests for CDC assistance to
investigate an apparent and
unexplained potential cluster or
increase in suicidal behavior. Rapid
Response Suicide Investigation Data
Collections are specifically designed to
inform the implementation of
prevention strategies in a state, county,
community, or vulnerable population
where a possible suicide cluster or
increasing trend has been observed.
This generic clearance will not be used
to conduct research studies or to collect
data designed to draw conclusions
about the United States or areas beyond
the defined geographic location or
vulnerable population that is the focus
of the investigation.
These public health data are used by
external partners (e.g., local, state,
territory, and tribal health authorities;
other federal agencies; local and state
leaders; schools; or other partner
organizations) to identify, prioritize, and
implement strategies to prevent suicidal
behavior and suicide. Rapid Response
Suicide Investigation Data Collections
methods will vary and depend on the
unique circumstances of the urgent and
rapid response and objectives
determined by CDC. Investigations may
use descriptive and/or cohort- or casecontrol designs. Data collection modes
may include: (a) Archival record
abstraction; (b) face-to-face interview;
(c) telephone interview; (d) web-based
questionnaire; (e) self-administered
questionnaire; and (f) focus groups.
Multiple data collection designs and
modes are likely to be employed in a
single investigation. The subpopulation
will vary and depend on the unique
circumstances of the Rapid Response
Suicide Investigation Data Collections.
Requests for assistance may include a
state, county, community, or vulnerable
population. Suicide rates are increasing
across age-groups and vulnerable
populations, include, but are not limited
to, youth, middle-aged adults, active
duty service personnel, veterans, and
American Indian/Alaska Native
communities. Investigations likely will
often require collection of information
from 10 or more respondents. The data
analytic approach for the Rapid
Response Suicide Investigation Data
Collection will vary and depend on the
objectives and methods of the
investigation. Multiple analytical
strategies are likely to be employed in
a single investigation. This may include
descriptive analyses, logistic regression,
and temporal and spatial cluster
analyses. The goal of the analyses is to
inform suicide prevention strategies by
understanding (a) significant increases
in fatal or nonfatal suicidal behavior; (b)
the risk factors associated with trends of
fatal or nonfatal suicidal behavior; (c)
the groups most affected (e.g., gender,
age, location in community or state);
and (d) current risk and protective
factors and prevention opportunities.
The total estimated annualized burden
for this collection is 1,000 hours. The
only cost to respondents will be time
spent responding to the surveys.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Rapid Response Suicide Investigation Data
Collection Participants.
daltland on DSKBBV9HB2PROD with NOTICES
Type of respondents
Rapid Response Suicide Investigation Data
Collection Instruments.
VerDate Sep<11>2014
17:40 Jun 29, 2018
Jkt 244001
PO 00000
Frm 00031
Fmt 4703
Sfmt 9990
E:\FR\FM\02JYN1.SGM
2,000
02JYN1
Number of
responses per
respondent
1
Average
burden per
response
(in hours)
30/60
30940
Federal Register / Vol. 83, No. 127 / Monday, July 2, 2018 / Notices
Jeffrey M. Zirger,
Acting Chief, Office of Scientific Integrity,
Office of the Associate Director for Science,
Office of the Director, Centers for Disease
Control and Prevention.
[FR Doc. 2018–14172 Filed 6–29–18; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–2027]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Survey of Current
Manufacturing Practices for the
Cosmetics Industry
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on a new information
collection: A survey of the cosmetics
industry on their current manufacturing
practices.
DATES: Submit either electronic or
written comments on the collection of
information by August 31, 2018.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before August 31,
2018. The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of August 31, 2018.
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date.
daltland on DSKBBV9HB2PROD with NOTICES
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
VerDate Sep<11>2014
17:40 Jun 29, 2018
Jkt 244001
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2018–N–2027 for ‘‘Agency Information
Collection Activities; Proposed
Collection; Comment Request; Survey of
Current Manufacturing Practices for the
Cosmetics Industry.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between
9 a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Ila
S. Mizrachi, Office of Operations, Food
and Drug Administration, Three White
Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–7726, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
E:\FR\FM\02JYN1.SGM
02JYN1
]]>Agencies
[Federal Register Volume 83, Number 127 (Monday, July 2, 2018)]
[Notices]
[Pages 30938-30940]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-14172]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-18-18CV]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled Rapid Response Suicide Investigation Data
Collection to the Office of Management and Budget (OMB) for review and
approval. CDC previously published a ``Proposed Data Collection
Submitted for Public Comment and Recommendations'' notice on November
9, 2017 to obtain comments from the public and affected agencies. CDC
did not receive comments related to the previous notice. This notice
serves to allow an additional 30 days for public and affected agency
comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
[[Page 30939]]
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to [email protected]. Direct written comments
and/or suggestions regarding the items contained in this notice to the
Attention: CDC Desk Officer, Office of Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by fax to (202) 395-5806. Provide
written comments within 30 days of notice publication.
Proposed Project
Rapid Response Suicide Investigation Data Collection--New--National
Center for Injury Prevention and Control (NCIPC), Centers for Disease
Control and Prevention (CDC)
Background and Brief Description
CDC is frequently called upon to respond to urgent requests from
one or more external partners (e.g., local, state, territory, and
tribal health authorities; other federal agencies; local and state
leaders; schools; or other partner organizations) to conduct
investigations of suicide. Supporting rapid investigations to inform
the implementation of effective suicide prevention strategies is one of
the most important ways CDC can serve to protect and promote the health
of the public. Prior to this request, CDC had collected data for a
suicide investigation via the OMB-approved Emergency Epidemic
Investigations (EEI) ICR (OMB No. 0920-1011; expiration 3/31/2020),
which supported data collections for Epi-Aid investigations. However,
this mechanism is no longer available for rapid suicide responses due
to the narrowing in scope of that generic. CDC requests approval for a
3-year period for this Generic Information Collection Request to
rapidly respond to urgent requests for CDC assistance to investigate an
apparent and unexplained potential cluster or increase in suicidal
behavior. Rapid Response Suicide Investigation Data Collections are
specifically designed to inform the implementation of prevention
strategies in a state, county, community, or vulnerable population
where a possible suicide cluster or increasing trend has been observed.
This generic clearance will not be used to conduct research studies or
to collect data designed to draw conclusions about the United States or
areas beyond the defined geographic location or vulnerable population
that is the focus of the investigation.
These public health data are used by external partners (e.g.,
local, state, territory, and tribal health authorities; other federal
agencies; local and state leaders; schools; or other partner
organizations) to identify, prioritize, and implement strategies to
prevent suicidal behavior and suicide. Rapid Response Suicide
Investigation Data Collections methods will vary and depend on the
unique circumstances of the urgent and rapid response and objectives
determined by CDC. Investigations may use descriptive and/or cohort- or
case-control designs. Data collection modes may include: (a) Archival
record abstraction; (b) face-to-face interview; (c) telephone
interview; (d) web-based questionnaire; (e) self-administered
questionnaire; and (f) focus groups. Multiple data collection designs
and modes are likely to be employed in a single investigation. The
subpopulation will vary and depend on the unique circumstances of the
Rapid Response Suicide Investigation Data Collections. Requests for
assistance may include a state, county, community, or vulnerable
population. Suicide rates are increasing across age-groups and
vulnerable populations, include, but are not limited to, youth, middle-
aged adults, active duty service personnel, veterans, and American
Indian/Alaska Native communities. Investigations likely will often
require collection of information from 10 or more respondents. The data
analytic approach for the Rapid Response Suicide Investigation Data
Collection will vary and depend on the objectives and methods of the
investigation. Multiple analytical strategies are likely to be employed
in a single investigation. This may include descriptive analyses,
logistic regression, and temporal and spatial cluster analyses. The
goal of the analyses is to inform suicide prevention strategies by
understanding (a) significant increases in fatal or nonfatal suicidal
behavior; (b) the risk factors associated with trends of fatal or
nonfatal suicidal behavior; (c) the groups most affected (e.g., gender,
age, location in community or state); and (d) current risk and
protective factors and prevention opportunities. The total estimated
annualized burden for this collection is 1,000 hours. The only cost to
respondents will be time spent responding to the surveys.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Rapid Response Suicide Investigation Rapid Response Suicide 2,000 1 30/60
Data Collection Participants. Investigation Data
Collection Instruments.
----------------------------------------------------------------------------------------------------------------
[[Page 30940]]
Jeffrey M. Zirger,
Acting Chief, Office of Scientific Integrity, Office of the Associate
Director for Science, Office of the Director, Centers for Disease
Control and Prevention.
[FR Doc. 2018-14172 Filed 6-29-18; 8:45 am]
BILLING CODE 4163-18-P
